Blog

Arc Minerals (LSE:ARCM) has reported solid progress during the second quarter as it prepares to begin drilling at its Virgo copper project in Botswana’s Kalahari Copper Belt. The company is close to completing its geophysical survey, with drilling expected to commence in August following a £3 million fundraising that fully finances the current exploration programme and provides additional working capital.

Legal Resolution Clears Path for Kabompo West

Arc has also reached a comprehensive settlement in Zambia, bringing all legal disputes relating to its Kabompo West project to an end. The agreement removes a key source of uncertainty and allows the company to concentrate on advancing the project.

Management is pursuing a dual-track strategy for Kabompo West, combining ongoing discussions with major mining companies alongside further technical evaluation. This work may also include AI-assisted analysis of geological data, with the aim of enhancing the project’s value and supporting future development opportunities within one of Africa’s leading copper-producing regions.

Financial Outlook Still Constrained

Despite operational progress, Arc Minerals’ investment outlook continues to be limited by its financial profile. As a pre-revenue exploration company, it remains loss-making, continues to generate negative cash flow and experienced a reduction in equity and total assets during 2025.

Technical indicators provide a more encouraging picture, with the share price trading above key moving averages and a positive MACD suggesting improving momentum. However, valuation remains difficult to assess due to the absence of earnings and a dividend.

More about Arc Minerals

Arc Minerals Ltd is an AIM-listed copper exploration company focused on developing high-potential assets across two of Africa’s most prospective copper belts. Its flagship Virgo Project is located within Botswana’s Kalahari Copper Belt, close to MMG’s Zone 5 corridor, while the Kabompo West project is situated in Zambia’s Western Domes region of the Central African Copper Belt.

Led by a management team with experience in mining, finance and African resource development, the company is focused on advancing its exploration assets through geological studies, drilling programmes and strategic partnerships. Its objective is to unlock value from large-scale copper opportunities in Botswana and Zambia.

Genedrive (LSE:GDR) has received a significant boost after UK Health Minister Preet Kaur Gill highlighted the company’s MT-RNR1 ID Kit during a parliamentary inquiry examining NHS innovation. The minister pointed to rapid pharmacogenetic testing to help prevent antibiotic-induced hearing loss in newborns as a practical example of personalised medicine in action.

The CE-IVD approved test, developed in collaboration with Manchester University NHS Foundation Trust and its partners, is being introduced across NHS neonatal intensive care units through the PALOH-UK programme. The technology is already in routine clinical use in Manchester and Sussex, with additional NHS hospitals considering implementation, strengthening Genedrive’s position in the precision diagnostics market.

NHS Rollout Supports Precision Medicine Strategy

Genedrive’s product portfolio focuses on rapid point-of-care pharmacogenetic testing designed to support faster and more informed prescribing decisions in urgent clinical settings. Alongside the MT-RNR1 newborn hearing loss test, the company also offers the CYP2C19 stroke test, helping clinicians tailor treatments based on a patient’s genetic profile.

By generating growing real-world clinical evidence through NHS deployment, Genedrive aims to support wider adoption of its technologies both in the UK and internationally. The ministerial recognition is expected to reinforce confidence among healthcare providers and policymakers while raising the company’s profile within the expanding personalised medicine sector.

Financial Outlook Remains Mixed

Despite the positive commercial momentum, Genedrive’s investment outlook continues to be constrained by weak financial performance. The company remains loss-making, continues to consume cash and has experienced a decline in shareholder equity, although debt levels remain relatively low.

Technical indicators provide some support, with the shares trading above key moving averages and momentum signals remaining broadly neutral. However, valuation remains difficult to justify given the absence of earnings and a dividend.

More about Genedrive

Genedrive plc is a UK-based commercial-stage diagnostics company specialising in rapid point-of-care pharmacogenetic testing. Its products are designed to improve the safety and effectiveness of prescribing decisions in emergency and acute healthcare settings by providing clinicians with fast genetic insights.

The company’s portfolio includes the CE-IVD approved and NICE-recommended Genedrive CYP2C19 ID Kit for stroke patients and the Genedrive MT-RNR1 ID Kit, which helps identify newborns at risk of antibiotic-induced hearing loss. Through continued NHS adoption and international expansion, Genedrive is seeking to establish its technologies as part of routine precision medicine practice.

Shuka Minerals (LSE:SKA) has completed the sixth and seventh drill holes, KBDD06 and KBDD07, at its Kabwe Zinc Mine in Zambia, with both holes successfully intersecting zinc mineralisation in the previously unmined Speaks and Mine Club areas. Located more than one kilometre northwest of the currently assessed Pit 2 zone, the drilling also confirmed the presence of the Kabwe host dolomites together with multiple mineralised zinc veins at several depths.

Drilling Programme Expanded to 2,500 Metres

Portable XRF analysis from the latest drill holes identified continuous zinc mineralisation, although average grades were lower than those recorded in earlier drilling. Several higher-grade intervals were also encountered, providing further evidence that the mineralised orebodies extend into the northern part of the project area.

Encouraged by the results, Shuka has expanded its initial drilling campaign to a total of 2,500 metres and has already begun drilling hole KBDD08. The additional work is intended to improve the geological understanding of the northern orebody and support future resource estimation and mine development planning.

Financial Challenges Continue to Weigh on Outlook

Despite the positive exploration update, Shuka’s investment outlook remains constrained by weak financial performance. The company continues to report losses, negative gross profit and recurring cash outflows, although its balance sheet has historically maintained relatively modest leverage.

Technical indicators also remain weak, with the share price trading below key moving averages and a negative MACD pointing to continued downward momentum. While oversold conditions are emerging, they have yet to provide a clear signal of a sustained recovery. Valuation also remains difficult to justify given the company’s loss-making position and the absence of a dividend.

More about Shuka Minerals Plc

Shuka Minerals Plc is an Africa-focused mining company listed on AIM in London, with a secondary listing on the AltX of the Johannesburg Stock Exchange. Its principal asset is the Kabwe Zinc Mine in Zambia, where it is exploring and developing deposits containing zinc, lead, copper, silver and vanadium oxide.

The Kabwe Project includes several mineralised zones, including Pit 2, Speaks and Mine Club, with mineral resources reported under NI 43-101 standards. The company is continuing to expand its drilling programme to better define the extent of mineralisation, support future mine planning and strengthen its position in the African base metals sector.

Thruvision Group plc (LSE:THRU), a developer of AI-powered walk-through security screening technology, has announced that its 8108 WalkTHRU system has been evaluated using the UK Government’s National Protective Security Authority (NPSA) Discriminative Threat Detection Systems Test Method. The assessment examined the system’s ability to screen non-divested individuals for potential mass-casualty threats, including both metallic and non-metallic concealed items, in high-throughput environments.

Independent Assessment Supports Performance Benchmarking

The NPSA confirmed that Thruvision correctly applied the prescribed testing methodology and stated that the published results accurately represent the system’s performance. It also noted that the assessment is not designed as a pass-or-fail process and should not be interpreted as an endorsement of the product.

The results are now available to security professionals and procurement teams, providing an independent benchmark for evaluating detection capability and screening throughput. The information may assist organisations assessing security technologies for sites exposed to evolving public safety risks.

Financial Performance Continues to Weigh on Outlook

Despite the successful assessment, Thruvision’s investment outlook remains constrained by weak financial performance. The company continues to report losses, significant pressure on gross margins and consistently negative operating and free cash flow, although its relatively low debt levels provide some financial stability.

Technical indicators also remain unfavourable, with the shares trading below all major moving averages, a negative MACD signalling weak momentum and an RSI pointing to continued market weakness. Valuation offers limited support, as the company remains loss-making and does not currently provide a dividend yield.

More about Thruvision Group plc

Thruvision Group plc is a UK-based designer, manufacturer and supplier of advanced walk-through security screening systems used by government agencies and commercial organisations in more than 30 countries. The company’s patented AI-enabled technology is designed to detect concealed objects in real time while allowing people to pass through screening without removing clothing or personal items.

Its flagship 8108 WalkTHRU system is designed for high-footfall environments, including retail distribution centres, sports venues and aviation workforce screening, where it can process up to 1,800 people per hour. The technology is intended to help identify both metallic and non-metallic concealed threats while maintaining efficient passenger and workforce flow.

Avingtrans PLC (LSE:AVG) has announced a proposed conditional placing of 3,309,000 new ordinary shares at 630 pence each, aiming to raise approximately £21 million. The fundraising represents around 9.8% of the company’s existing issued share capital and is not underwritten or subject to shareholder approval.

The placing includes participation from Chairman Roger McDowell, alongside a blue-chip institutional cornerstone investor that has committed up to £11 million.

Proceeds Target U.S. Nuclear Growth

After expenses, Avingtrans expects to receive net proceeds of approximately £19.9 million. The capital will be used primarily to expand the group’s nuclear manufacturing capabilities in the United States, including the development of its Michigan facility, investment in new production equipment, workforce growth, and additional working capital and contingency funding.

Management believes the investment will significantly increase the scale of its nuclear operations, with annual nuclear revenue projected to rise from around £35 million to approximately £90 million by 2031. The expansion is intended to strengthen Avingtrans’ position as a key supplier to emerging nuclear projects, supported by increasing demand linked to energy security, decarbonisation and expanding digital infrastructure.

Financial Outlook Remains Positive

Avingtrans continues to benefit from solid underlying financial performance, supported by revenue growth, improving profitability, low leverage and stronger free cash flow generation.

While technical indicators suggest the shares may be trading in overbought territory following a sustained upward trend, the broader outlook remains constructive. Valuation appears reasonable, although income investors may find limited support from the current dividend yield.

More about Avingtrans

Avingtrans PLC is an AIM-listed engineering group that designs, manufactures and supplies critical components, systems and specialist services to customers across the energy, medical and industrial sectors.

Through its Advanced Engineering Systems division, which includes businesses such as Hayward Tyler and Energy Steel, the company has established a strong presence in global nuclear markets. Its expertise spans nuclear new-build projects, plant life extension, decommissioning programmes and fusion energy applications, positioning the group to benefit from long-term growth in the nuclear sector.

Clean Power Hydrogen plc (LSE:CPH2), the AIM-listed green hydrogen technology company, has announced that CEO Elect Richard Scott will host a live online investor presentation on 21 July 2026 through the Investor Meet Company platform. The session will outline the group’s strategic transition towards a capital-light business model centred on technology development and global licensing.

The company develops patented electrolysis technology designed to produce low-cost hydrogen and oxygen for decentralised and alternative energy markets. Drawing on more than a decade of research, Clean Power Hydrogen has built a portfolio of granted and pending patents that forms the foundation of its technology-led strategy.

Investor Presentation to Highlight Strategic Shift

The online event will be open to both existing and prospective shareholders, providing an opportunity for management to explain the company’s new direction and answer investor questions.

Clean Power Hydrogen’s revised strategy focuses on commercialising its intellectual property through international licensing partnerships rather than relying on capital-intensive manufacturing. Management believes this approach has the potential to reduce funding requirements while broadening the company’s global market reach.

Financial Outlook Remains Challenging

Despite the strategic shift, the company’s investment outlook continues to be constrained by weak financial fundamentals. Clean Power Hydrogen generates limited revenue, remains loss-making and continues to report negative free cash flow, highlighting its ongoing dependence on external funding.

Technical indicators also remain negative, with the share price trading well below key moving averages and bearish momentum signals pointing to continued weakness. Valuation offers little support given the absence of earnings and the lack of a dividend yield.

More about Clean Power Hydrogen PLC

Clean Power Hydrogen plc is a UK-based developer of green hydrogen technology focused on advanced electrolysis systems for the production of hydrogen and oxygen. The company has built a portfolio of granted and pending patents designed to reduce the lifetime cost of hydrogen production across decentralised energy and alternative fuel markets.

As an AIM-listed technology business, Clean Power Hydrogen is increasingly focused on licensing its intellectual property and expanding through strategic partnerships rather than manufacturing infrastructure. Its long-term objective is to make hydrogen production more cost-effective while growing its presence in the global clean energy sector.

Dekel Agri-Vision (LSE:DKL) reported a strong operational performance for the first half of 2026, with both its palm oil and cashew divisions recording significant growth in Côte d’Ivoire. At the Ayenouan palm oil operation, fresh fruit bunch throughput increased by 11.5%, driving a 7.3% rise in crude palm oil production and a 5.0% increase in sales volumes, with almost all output successfully sold into the resilient domestic market.

Palm Oil Business Positioned for Stronger Second Half

Average palm oil prices remained broadly unchanged from a year earlier, although elevated international benchmark prices continue to indicate potential for higher local pricing as seasonal production slows later in the year.

Palm kernel oil volumes declined during the period as kernel inventories increased. However, management expects these stocks to be processed during the low-production season, supporting improved palm kernel oil production and sales in the second half of the year.

Cashew Division Records Rapid Expansion

The company’s cashew processing facility at Tiebissou delivered particularly robust growth during the period. Raw cashew nut processing rose by 45.7%, finished cashew production increased by 82.0%, and sales volumes more than doubled compared with the same period last year.

Operational improvements, including higher extraction rates and a stronger ratio of whole nuts to broken nuts, contributed to the performance. Growth was also supported by increased processing of third-party raw cashews, including a newly introduced specialised unpeeled product that generates margins comparable to those achieved using Dekel’s own raw materials.

Higher Volumes Offset Softer Cashew Prices

Although average prices for peeled cashews declined by 22.1% amid weaker global market conditions and a return to more normal pricing after last year’s elevated levels, the sharp increase in production and sales volumes highlights the successful expansion of the processing facility.

The combined progress across the group’s palm oil and cashew operations reflects improving utilisation of its production assets and reinforces Dekel’s position as an expanding regional agricultural producer, with the potential to support revenue and profitability as the year advances.

Outlook Remains Constrained by Financial Performance

Despite the operational improvements, Dekel’s investment outlook continues to be weighed down by ongoing financial challenges. The company remains loss-making, carries significant leverage, has experienced declining shareholder equity and returned to negative cash flow during 2025.

Technical indicators also remain weak, with the shares trading below key moving averages and a negative MACD signalling continued downward momentum. While the RSI suggests the stock is approaching oversold territory, valuation remains difficult to justify given the absence of earnings and a dividend.

More about Dekel Agri-Vision

Dekel Agri-Vision Plc is an agribusiness company focused on developing sustainable agricultural operations in Côte d’Ivoire. Its core assets include the Ayenouan crude palm oil mill, which processes fruit supplied by local smallholders, and the expanding cashew processing facility at Tiebissou.

The company is pursuing a diversified strategy centred on palm oil and cashews, with continued investment in processing capacity and operational efficiency. By supplying both domestic and international markets, Dekel aims to strengthen its position within West Africa’s agricultural value chain while driving long-term growth through value-added food production.